Breaking News Instant updates and real-time market news.

TXRH

Texas Roadhouse

$61.13

0.67 (1.11%)

, CREE

Cree

$58.39

1.12 (1.96%)

10:00
03/20/19
03/20
10:00
03/20/19
10:00

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Texas Roadhouse (TXRH) upgraded to Overweight from Equal Weight at Stephens with analyst Will Slabaugh saying he thinks the company can deliver better than expected same-store sales and EPS growth as it implements a price increase at the beginning of Q2. 2. Cree (CREE) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha stating he believes that he has been too conservative on the valuation front given his view that Cree "is positioned squarely at the center of some of the most interesting developments in the electronics business." 3. Nevro (NVRO) upgraded to Outperform from Market Perform at Wells Fargo with analyst Lawrence Biegelsen noting that incoming CEO Keith Grossman has successfully turned around the previous two companies he led and saying he is "highly confident" he will be successful in turning around Nevro. 4. Dollar Tree (DLTR) upgraded to Outperform from Market Perform at Telsey Advisory with analyst Joseph Feldman saying meetings with management gave him increased visibility and confidence in the company's plan and he believes Dollar Tree should see a return to earnings growth in the second half of 2019. 5. Whiting Petroleum (WLL) upgraded to Overweight from Equalweight at Capital One citing an increased oil price deck. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TXRH

Texas Roadhouse

$61.13

0.67 (1.11%)

CREE

Cree

$58.39

1.12 (1.96%)

NVRO

Nevro

$60.76

16 (35.75%)

DLTR

Dollar Tree

$101.35

0.06 (0.06%)

WLL

Whiting Petroleum

$24.87

0.28 (1.14%)

  • 20

    Mar

  • 21

    Mar

  • 02

    Apr

  • 01

    May

TXRH Texas Roadhouse
$61.13

0.67 (1.11%)

03/20/19
SPHN
03/20/19
UPGRADE
Target $70
SPHN
Overweight
Texas Roadhouse upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Will Slabaugh upgraded Texas Roadhouse to Overweight from Equal Weight as he thinks the company can deliver better than expected same-store sales and EPS growth as it implements a price increase at the beginning of Q2. The analyst, who expects the company's "impressive" traffic growth trajectory to continue, keeps a $70 price target on Texas Roadhouse shares.
02/20/19
LOOP
02/20/19
NO CHANGE
Target $67
LOOP
Hold
Texas Roadhouse EPS capped by labor costs, says Loop Capital
Loop Capital analyst Lynne Collier kept her Hold rating and $67 price target on Texas Roadhouse after its Q4 results, saying that while the comps were better than expected, earnings came in line because of the higher labor and SG&A costs. The analyst notes that the traffic growth and same-store sales for the company are "virtually unmatched", but sees the stock trading "range-bound" in the near term because of continued margin pressure.
01/11/19
GSCO
01/11/19
DOWNGRADE
Target $68
GSCO
Neutral
Starbucks downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Karen Holthouse downgraded Starbucks to Neutral and lowered her price target for the shares to $68 from $75. The coffee giant closed yesterday up 31c to $64.19. The analyst remains "reasonably confident" that Starbucks' initiatives to drive digital engagement can lead to a "more stable" 3%-4% comp trajectory in the U.S. over the next few years. However, its valuation has "rapidly re-rated" to reflect this, and gift cards and digital trends could be points of caution in fiscal Q1, Holthouse tells investors in a research note. Further, she has "incremental concerns" regarding the China macro environment and the company's comp trajectory in that region. Other consumer companies, like Apple (AAPL) and McDonald's (MCD), have noted weakness in China, the analyst points out. Holthouse this morning also upgraded Texas Roadhouse (TXRH) to Buy from Neutral and downgraded Yum! Brands (YUM) to Sell from Neutral.
01/22/19
STFL
01/22/19
DOWNGRADE
Target $70
STFL
Hold
Texas Roadhouse downgraded to Hold from Buy at Stifel
Stifel analyst Chris O'Cull downgraded Texas Roadhouse to Hold with a price target of $70 based on its premium valuation, saying the stock currently sells "nearly two standard deviations higher than the 10-year historical average". While he sees the price as reflective of the company's long-term growth outlook, he sees its potential for earnings upside as limited in the near term because of his forecast for higher costs.
CREE Cree
$58.39

1.12 (1.96%)

03/20/19
JMPS
03/20/19
UPGRADE
Target $74
JMPS
Outperform
Cree upgraded to Outperform after industry conference at JMP Securities
As previously reported, JMP Securities analyst Joseph Osha upgraded Cree to Outperform from Market Perform after attending the Applied Power Electronics Conference, which he said underscored the extent to which wide bandgap materials are becoming the default solution in high-voltage power electronics. After attending the APEC event and meeting with a senior CREE executive along with the CTO of the PowerAmerica consortium, the analyst now thinks that he has been too conservative on the valuation front given his view that Cree "is positioned squarely at the center of some of the most interesting developments in the electronics business." Osha, who also cites the fact that the company's troubled lighting business is being sold, has a $74 price target on Cree shares.
03/20/19
JMPS
03/20/19
UPGRADE
JMPS
Outperform
Cree upgraded to Outperform from Market Perform at JMP Securities
01/29/19
01/29/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nvidia (NVDA) downgraded to Equal Weight from Overweight at Morgan Stanley and to Underperform from Buy at Needham. 2. Square (SQ) downgraded to Underperform from Market Perform at Raymond James with analyst John Davis saying he thinks organic growth peaked in Q3 of 2018 and expects growth in subs and services to materially decelerate in Q2 as acquisitions of Weebly and Zesty move into the base with their slower growth. 3. AK Steel (AKS) downgraded to Neutral from Outperform at Macquarie with analyst David Lipschitz saying while its Q4 earnings topped consensus, the company's margin improvements from contract renewals were "less than expected," adding that earnings could face "further downside risks as the current steel pricing environment stays weak and raw material costs continue to rise." 4. Cree (CREE) downgraded to Market Perform from Outperform at JMP Securities with analyst Joseph Osha saying he sees no signs at the moment that competing suppliers, including Chinese firms, are catching up with Cree in terms of its dominance in silicon carbide materials and devices. 5. Fortis (FTS) downgraded to Hold from Buy at TD Securities with analyst Linda Ezergailis citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/19
OPCO
01/31/19
NO CHANGE
Target $59
OPCO
Outperform
Cree price target raised to $59 from $53 at Oppenheimer
Oppenheimer analyst Colin Rusch raised his price target for Cree to $59 from $53 as he sees lower risk to 2020 estimates due to strong SiC demand and improved operational performance. The analyst believes Cree remains supply constrained through at least 2020 for its SiC materials even as it doubles capacity, continues to see significant growth in EV demand, particularly in China, and believes the U.S. and EU will hit tipping points for growth in 2021 and 2022. Rusch reiterates an Outperform rating on the shares.
NVRO Nevro
$60.76

16 (35.75%)

03/20/19
MSCO
03/20/19
UPGRADE
Target $70
MSCO
Overweight
Morgan Stanley sees 'new beginning' for Nevro, double upgrades to Overweight
Morgan Stanley analyst David Lewis upgraded Nevro to Overweight from Underweight, telling investors that management changes announced yesterday and the new platform disclosed at NANS 2019 represent "a new beginning" with a material change in strategy. He also reads the changes as evidence that the board is more committed to execution and shareholder returns, Lewis tells investors. He raised his price target on Nevro shares to $70 from $41. Nevro has also been upgraded at Wells Fargo, BofA/Merrill Lynch, JPMorgan and BMO Capital.
03/20/19
WELS
03/20/19
UPGRADE
Target $75
WELS
Outperform
Nevro upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen upgraded Nevro to Outperform from Market Perform after the company announced that it was replacing its current CEO, Rami Elghandour, with Keith Grossman and adding Bess Weatherman and Kevin O'Boyle to the Board. The analyst notes that Grossman has successfully turned around the previous two companies he led as CEO, and says he is "highly confident" he will be successful in turning around Nevro. Further, Biegelsen believes the company has a good product, participates in a healthy, underpenetrated market, and has a "strong and under-appreciated pipeline." The analyst also raised his price target on the shares to $75 from $50.
03/20/19
ADAM
03/20/19
NO CHANGE
Target $62
ADAM
Buy
Nevro price target raised to $62 from $46 at Canaccord
Canaccord analyst Jason Mills reiterated a Buy rating on Nevro and raised his price target to $62 from $46, telling investors in a research note that he recommends adding to/building positions on the post-close announcement that Keith Grossman will immediately take on the roles of president and CEO. Mills says he has known Grossman for nearly 20 years, and says Grossman has "proven to be one of the best CEO executors in med-tech."
03/20/19
03/20/19
UPGRADE
Target $70

Buy
Nevro upgraded to Buy, new CEO 'best in class,' says BofA/Merrill
As previously reported, BofA/Merrill upgraded Nevro to Buy from Neutral and raised its price target to $70 from $50. Analyst Bob Hopkins said new CEO Keith Grossman is the "best SMid cap commercial turn-around CEO in MedTech." The analyst said Mr. Grossman's sill set is well suited to address Nevro's current challenges combined with a healthy addressable market and full pipeline.
DLTR Dollar Tree
$101.35

0.06 (0.06%)

03/20/19
03/20/19
UPGRADE
Target $117

Outperform
Dollar Tree upgraded to Outperform on return to growth at Telsey Advisory
As previously reported, Telsey Advisory analyst Joseph Feldman upgraded Dollar Tree to Outperform from Market Perform after meeting with management. The analyst believes Dollar Tree should see a return to earnings growth in the second half of 2019, after heavy investments related to its transformation - Family Dollar remodels, re-bannering, store closing, store support center consolidation - followed by EPS growth of 14%-18% in 2020, with the double-digit trend to continue in 2021. Feldman also raised his price target on the shares to $117 from $103.
03/20/19
TLSY
03/20/19
UPGRADE
Target $117
TLSY
Outperform
Dollar Tree upgraded to Outperform from Market Perform at Telsey Advisory
Telsey Advisory analyst Joseph Feldman upgraded Dollar Tree to Outperform from Market Perform and raised his price target to $117 from $103 following meetings with CEO Gary Philbin, CFO Kevin Wampler and VP of IR Randy Guiler. In a research note to investors, Feldman says the meetings with management gave him increased visibility and confidence in the company's plan, and believes Dollar Tree should see a return to earnings growth in the second half of 2019, followed by EPS growth of 14%-18% in 2020, with the double digit trend continuing in 2021.
03/20/19
EVER
03/20/19
INITIATION
Target $105
EVER
In Line
Dollar Tree initiated with an In Line at Evercore ISI
Evercore ISI analyst Michael Montani started Dollar Tree with an In Line rating and $105 base case price target, citing his view that the company is taking the right steps to re-baseline the Family Dollar business and drive comp growth. However, given what he sees to be a challenging food/consumables market, he thinks the "risk-reward appears about right" at current levels.
03/20/19
TLSY
03/20/19
UPGRADE
TLSY
Outperform
Dollar Tree upgraded to Outperform from Market Perform at Telsey Advisory
WLL Whiting Petroleum
$24.87

0.28 (1.14%)

12/06/18
SPHN
12/06/18
INITIATION
Target $54
SPHN
Overweight
Whiting Petroleum initiated with an Overweight at Stephens
Stephens analysts Gail Nicholson and Drew Lipke began coverage of the E&P sector with a positive outlook, starting Whiting Petroleum with an Overweight rating and $54 price target.
03/20/19
SOCO
03/20/19
UPGRADE
SOCO
Overweight
Whiting Petroleum upgraded to Overweight from Equalweight at Capital One
Capital One upgraded Whiting Petroleum to Overweight citing gan increased oil price deck.
03/13/19
WELS
03/13/19
NO CHANGE
Target $36
WELS
Outperform
Whiting Petroleum price target lowered to $36 from $45 at Wells Fargo
Wells Fargo analyst Gordon Douthat lowered his price target for Whiting Petroleum to $36 from $45, while reiterating an Outperform rating on the shares. The analyst notes that while shares traded off on a Q4 capex miss, and above consensus capex in 2019 due to greater infrastructure spend, another headwind appears when observing well performance which showed degradation versus 2017 as the company customized completion designs to optimize rates of return rather than absolute productivity. The analyst believes that the underlying capital efficiency is somewhat masked by infrastructure and acreage spend setting up for improvements in 2020, but acknowledges that near-term execution on capital discipline and debt reduction is likely needed to bring back investors following Q4 results.
02/12/19
KEYB
02/12/19
INITIATION
Target $33
KEYB
Overweight
Whiting Petroleum initiated with an Overweight at KeyBanc
KeyBanc analyst Leo Mariani started Whiting Petroleum with an Overweight rating and $33 price target. The analyst likes the company's "consistent" free cash flow generation and its "likely beta reaction" to a continued oil price recovery.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.